In the present work, ligand-based drug design approach viz. consensus pharmacophoric analysis has been executed for antimycobacterial DprE1 inhibitory activity of substituted hydantoins to find out the associated important features for future optimizations. The methodology involves structure drawing, optimization, filed-based alignment and construction of pharmacophore model. The study point outs that H-bond donor and acceptor groups as well as aromatic rings are vital for the anti-malarial activity. The outcomes could be advantageous for optimization of 2-anilino 4-amino substituted quinazolines as anti-malarial agents.
INTRODUCTION
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a deadly disease with global presence but high occurrence in developing and undeveloped countries. It is a vector borne neglected disease and recent reports suggest the emergence of resistance against existing drugs. The emergence of resistance is cause of high concern; therefore, developing novel therapeutics is an urgent need to eliminate this lethal disease [1] [2] [3] . Unfortunately, developing a new drug is a lengthy and expensive exercise; therefore, alternative methods like Computer Aided Drug Designing (CADD) must be used to derive a new therapeutic agent. In recent time, CADD has gained popularity due to qualities like low cost, involvement of minimal animal testing, low resource demanding and result focused nature. Consequently, it has emerged as a method of choice for drug designing. CADD is a relatively new but highly successful branch. Ligand-based drug design (LBDD), a branch of CADD, is widely used for drug optimization. Pharmacophore modeling and QSAR analysis are commonly used to identify key structural scaffold, especially when the 3D-structure of target enzyme, with which the drug interact, is unknown. Consensus pharmacophore modeling is extensively utilized as it is fast, easy and identifies the common pharmacophoric scaffolds associated with the anticipated activity [4] [5] [6] . Recently, Rogacki et al [3] identified hydantoin derivatives as potent anti-TB compounds. The tested hydantoin derivatives have high degree of variation in anti-TB profile because of wide difference in substituents. Extensive structure-activity relationships (SAR) were discussed to identify key scaffolds. Nevertheless, this is first attempt to rationalize the pharmacophoric features/pattern related with anti-TB activity of substituted hydantoins. Therefore, in the present work, consensus pharmacophore modeling was performed to find the noteworthy structural features that decide the anti-TB activity of hydantoin derivatives.
MATERIALS AND METHODS

Dataset
The dataset consists of ninety-five hydantoin derivatives with a variety of substituents like heterocyclic rings, -CN, -OCH 3 , -Br, different types of isomers, etc. Therefore, the selected dataset covers substantial chemical space. The compounds were tested for anti-TB activity (decaprenylphospho-beta-D-ribofuranose 2-oxidase i.e. DprE1). The activity values described as DprE1 pIC 50 range from 4 to 7.4. The dataset has been tabulated in Table 1 . Table 1 . Different substituted hydantoin derivatives (SMILES notation) along with reported DprE1 pIC 50 used in the present work. 
S.N. SMILES
DprE1 pIC50 1. O=C1N(C(C(C)(N1)C2=CC=C(C#N)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 7 2. O=C1N(CC(C2=CC=C(Br)C=C2)=O)C(C(C3=CC=C(OC)C=C3)(CC)N1)=O 6.8 3. O=C1N(CC(C2=CC=C(Cl)S2)=O)C(C(C3=CC=C(Cl)C=C3)(C)N1)=O 6.4 4. O=C1N(CC(C2=CC=C(F)C=C2F)=O)C(C(C3=CC=CC=C3)(C)N1)=O 4.4 5. C[C@@]1(NC(=O)N(CC(=O)c2ccc(F)cc2F)C1=O)c1ccc(cc1)C#N 7.2 6. C[C@]1(NC(=O)N(CC(=O)c2ccc(F)cc2F)C1=O)c1ccc(cc1)C#N 4.2 7. COc1ccc(cc1)C1(C)NC(=O)N(CC(=O)c2ccc(F)cc2F)C1=O 6.7 8. CC1(NC(=O)N(CC(=O)c2ccc(F)cc2F)C1=O)c1ccc(Cl)cc1 6.7 9. CC1(NC(=O)N(CC(=O)c2ccc(F)cc2)C1=O)c1ccc(cc1)C#N 6 10. COc1ccc(cc1)C1(C)NC(=O)N(CC(=O)c2ccc(F)cc2)C1=O 6 11. CC1(NC(=O)N(CC(=O)c2ccc(F)cc2)C1=O)c1ccc(Cl)cc1 4.2 12. CC1(NC(=O)N(CCC(=O)c2ccc(F)cc2)C1=O)c1ccc(cc1)C#N 4.3 13. COc1ccc(cc1)C1(C)NC(=O)N(CCC(=O)c2ccc(F)cc2)C1=O 4.4 14. CC(N1C(=O)NC(C)(C1=O)c1ccc(cc1)C#N)C(=O)c1ccc(F)cc1F 5.4 15. CC1(NC(=O)N(C2Cc3cc(F)cc(F)c3C2=O)C1=O)c1ccc(cc1)C#N 4.6 16. CC1(NC(=O)N(CCOc2ccc(F)cc2F)C1=O)c1ccc(cc1)C#N 4.4 17. O=C1N(CC(F)(F)C2=CC=C(F)C=C2F)C(C(C3=CC=C(C#N)C=C3)(C)N1)=O 5 18. COc1ccc(cc1)C1(C)NC(=O)N(CC(O)c2ccc(F)cc2F)C1=O 4.2 19. O=C1N(C(C(C)(N1)C2=CC=C(Br)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 7.1 20. O=C1N(C(C(C)(N1)C2=CC=C(C)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 6.1 21. O=C1N(C(C(C)(N1)C2=CC=C(OCC)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 7 22. O=C1N(C(C(C)(N1)C2=CC=C(C(F)(F)F)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 6.9 23. O=C1N(C(C(C)(N1)C2=CC=C(OC(F)(F)F)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 7.3 24. O=C1N(C(C(C)(N1)C2=CC=C(OC(F)F)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 7.4 25. O=C1N(C(C(C)(N1)C2=CC=C(N3C=NC=C3)C=C2)=O)CC(C4=CC=C(C=C4F)F)=O 6.5 26. O=C1N(C(C(C)(N1)C2=CC=C(N3C=NN=N3)C=C2)=O)CC(C4=CC=C(C=C4F)F)=O 7.3 27. O=C1N(C(C(C)(N1)C2=CC=C(N3CCOCC3)C=C2)=O)CC(C4=CC=C(C=C4F)F)=O 7.1 28. O=C1N(C(C(C)(N1)C2=CC=C(N3CCOC3=O)C=C2)=O)CC(C4=CC=C(C=C4F)F)=O 6.6 29. O=C1N(C(C(C)(N1)C2=CC=C(NC(C)=O)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 5.6 30. O=C1N(C(C(C)(N1)C2=CC=C(S(C)(=O)=O)C=C2)=O)CC(C3=CC=C(C=C3F)F)=O 6.8 31. O=C1N(C(C(N1)(C2=CC(C#N)=CC=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 4.4 32. O=C1N(C(C(N1)(C2=CC(Br)=CC=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 4.5 33. O=C1N(C(C(N1)(C2=CC(F)=C(OC)C=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 5.7 34. O=C1N(C(C(N1)(C2=CC=C(OC)C=C2F)C)=O)CC(C3=CC=C(C=C3F)F)=O 6.5 35. O=C1N(C(C(N1)(C2=CC=C(Br)C=C2F)C)=O)CC(C3=CC=C(C=C3F)F)=O 6.7 36. O=C1N(C(C(N1)(C2=CC=C(OC(F)F)C(OC)=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 6.9 37. O=C1N(C(C(N1)(C2=CC=NC=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 4.
O=C1N(C(C(N1)(C2=CC=C(NS(=O)(C)=O)C=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 7 47. O=C1N(C(C(N1)(C2=CC=CC(NS(=O)(C)=O)=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 4.2 48. O=C1N(C(C(N1)(C2=CC=C(N)C=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 4.1 49. O=C1N(C(C(N1)(C2=CC=C(C#N)N=C2)C)=O)CC(C3=CC=C(C=C3F)F)=O 6 50. O=C1N(C(C(N1)(C2=CC=C(C#N)C=N2)C)=O)CC(C3=CC=C(
C=C3F)C=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7.2 57. O=C(N1CC(C2=CC=CC(F)=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.4 58. O=C(N1CC(C2=CC=CC=C2F)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7.3 59. O=C(N1CC(C2=CC=CC=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7.2 60. O=C(N1CC(C2=CC=C(OC)C=C2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 5.7 61. O=C(N1CC(C2=CC=C(OC)C=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.2 62. O=C(N1CC(C2=CC=CC(OC)=C2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 5.9 63. O=C(N1CC(C2=CC=CC=C2OC)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 4.4 64. O=C(N1CC(C2=CC=CC(C(F)(F)F)=C2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 6.6 65. O=C(N1CC(C2=CC=CC([N+]([O-])=O)=C2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 5.5 66. O=C(N1CC(C2=CC=NC=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.3 67. O=C(N1CC(C2=CC=CN=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 5.7 68. O=C(N1CC(C2=CC=CC=N2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.7 69. O=C(N1CC(C2=C(F)C=C(F)C=N2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 7 70. O=C(N1CC(C2=CC=CS2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.8 71. O=C(N1CC(C2=NC=CS2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 5.7 72. O=C(N1CC(C2=NC=CS2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.7 73. O=C(N1CC(C2CCCCC2)=O)C(C3=CC=C(C#N)C=C3)(C)NC1=O 5.7 74. O=C1N(CC(C2(C3)CC4CC3CC(C4)C2)=O)C(C(C5=CC=C(C#N)C=C5)(C)N1)=O 4.7 75. O=C(N1CC(N2CCCCC2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 5.3 76. O=C(N1CC(N2CCCC2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 4.6 77. O=C(N1CC(C2=CC=C3C(OCO3)=C2)=O)C(C4=CC=C(OC(F)F)C=C4)(C)NC1=O 6.6 78. O=C(N1CC(C2=CC=C(OC)C(F)=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 6.4 79. O=C(N1CC(C2=C(OC)C=CC(F)=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 5.4 80. O=C(N1CC(C2=C(C)C=CC(C)=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7 81. O=C(N1CC(C2=C(C)C=C(C)C=C2C)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 5 82. O=C(N1CC(C2=CC=C(C)S2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7 83. O=C(N1CC(C2=CC=C(Cl)S2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 7.2 84. O=C(N1CC(C2=CC=CN2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 4.3 85. O=C(N1CC(C2=C(C)NC(C)=C2)=O)C(C3=CC=C(OC(F)F)C=C3)(C)NC1=O 4.4 86. O=C1N(CC(C2=CC=C(F)C=C2F)=O)CC(C3=CC=C(OC)C=C3)(C)N1 4.5 87. CC1(NC(=O)N(CC(=NO)c2ccc(F)cc2F)C1=O)c1ccc(cc1)C#N 4 88. CC1(NC(=O)N(CC(=NO)c2ccc(F)cc2F)C1=O)c1ccc(cc1)C#N 4.2 89. CC1(c2ccc(Cl)cc2)NC(N(C1=O)CC(N3CCc4c3cccc4)=O)=O 6.2 90. Cc1sc(C)c(C(CN2C(NC(C2=O)(c3ccc(C)cc3)C)=O)=O)c1 6.2 91. CC1(c2ccc(C#N)cc2)NC(N(C1=O)CC(c3c(Cl)cccc3)=O)=O 6.2 92. COc1ccc(C(CN2C(NC(C2=O)(c3ccc(C(C)C)cc3)C)=O)=O)cc1 6.2 93. CC1(c2cc3c(CCC3)cc2)NC(N(C1=O)CC(c4cc(Br)ccc4)=O)=O 6.1 94. Cc1cc(C)c(C(CN2C(NC(C2=O)(c3ccc(Cl)cc3)C)=O)=O)cc1 5.7 95. CC1(c2ccc(F)cc2)NC(N(C1=O)CC(c3c(F)cccc3)=O)=O 4.2
Structure drawing, optimization and alignment
The various steps involved are (1) ChemSketch 12 freeware was used to draw ninety-five structures, (2) Structure optimization of all the structures using MMFF94 force field existing in TINKER, (3) In the next step, Open3dAlign software was executed to align all the optimized structures, (4) Consensus pharmacophore modeling was completed using LIQUID plugin (installed on PyMOl 2.2) using the default settings [4] [5] [6] .
RESULTS AND DISCUSSION
The consensus pharmacophore modeling recognized that the anti-TB activity of hydantoin derivatives is correlated with six main pharamcophoric features. The pharmacophoric pattern consists of five hydrophobic and one H-bond donor feature. The six features are again divided into two sets: (1) the first set comprises two hydrophobic features and one H-bond donor, (2) the second encompasses a triangular arrangement of three hydrophobic groups which are close to each other. The following figures depict this consensus pharmacophoric pattern along with their respective distances (shown using green color). 4. CONCLUSION Therefore, in future optimizations, the three-cornered arrangement of hydrophobic aromatic rings, one H-bond donor groups and two additional lipophilic centers close to it must be preserved for good anti-TB activity.
